bioRxiv Science⌕ Search

Biology subjects

Constantinescu, A.

Publications and source records attributed to Constantinescu, A..

2 recordsLinked to original sources

Aldehyde dehydrogenase 1A3 detection in extracellular vesicles from breast cancer cell lines by nano-flow cytometry

1.Exosomes are nanosized extracellular vesicles that carry bioactive molecules reflective of their cells of origin. Developing methods to detect functional enzymatic activity within exosomes can provide a new generation of rapid and informative diagnostic tools. Aldehyde dehydrogenase (ALDH) enzymes, particularly ALDH1A3, are overexpressed in several cancers and contribute to tumor aggressiveness and drug resistance. However, their presence and functionality in cancer-derived exosomes remain poorly characterized. Here, we developed a nano-flow cytometry-based method to detect ALDH activity directly within individual exosomes derived from breast cancer cell lines (SKBR3, MDA-MB-231, and MCF7). Exosomes were isolated by differential ultracentrifugation and validated by nanoparticle tracking analysis, cryogenic transmission electron microscopy, and bead-based immunophenotyping of canonical markers. ALDH enzymatic activity was detected using a resorufin-based fluorescent substrate capable of crossing the exosomal membrane. To ensure specificity, assays were performed in the presence or absence of a selective ALDH inhibitor, confirming that the fluorescent signal originated from ALDH activity within the vesicles. This work provides the first functional evidence of ALDH1A3 enzymatic activity in cancer-derived exosomes and establishes a proof-of-concept platform for rapid, activity-based detection of exosomal enzymes, opening new perspectives for exosome-based diagnostics in breast cancer.

Cell Biology↗

ALDH1 subtype-specific inhibitor targets key cell populations in triple negative breast cancer

Aggressive breast cancer subtypes, particularly triple-negative breast cancer (TNBC), lack effective targeted therapies, requiring novel approaches. This study focuses on the aldehyde dehydrogenase 1A (ALDH1A) subfamily, comprising ALDH1A1, ALDH1A2, and ALDH1A3, and their roles in tumor biology and the tumor microenvironment. Comprehensive transcriptomic and single-cell analyses revealed subtype- and cell-specific expression patterns of ALDH1A isoforms, with ALDH1A3 predominantly expressed in epithelial cancer cells of basal-like tumors, while ALDH1A1 and ALDH1A2 were expressed in stromal and immune-associated subpopulations. Guided by these findings, we developed ABD0171, a selective ALDH1A3 inhibitor that demonstrated potent isoform-specific activity. ABD0171 effectively disrupted key pathways in TNBC cells in vitro, including IL6/JAK/STAT3, tPA and Src/FAK, and exhibited superior selectivity, robust antitumor and antimetastatic effects, and a favorable safety profile in vivo. These results establish ALDH1A3 as a promising therapeutic target and validate ABD0171 as a candidate to address current challenges in aggressive breast cancers.

cancer biology↗